For AML, gene mutations such as DNMT3A, TET2, and ASXL1 recommended by the European Leukemia Network are common in clonal hematopoiesis and appear to be relatively early events in the development of leukemia (14), which also reveals the great potential of SNPs in the diagnosis, treatment, and prognosis assessment of AML. Here, ASXL1 is linked to acute myeloid leukemia.